Pentadecapeptide
A synthetic research peptide containing 15 amino-acid residues.
SRP COMPOUND INTELLIGENCE
BPC-157 Research Guide
An evidence-mapped overview of BPC-157 covering compound identity, preclinical research themes, proposed biological pathways, published studies, laboratory considerations, and current evidence limitations.
Evidence base: primarily preclinical
Investigational compound
Research use only
Educational information only. BPC-157 is not FDA-approved for human use.
COMPOUND
BPC
157
15 RESIDUES
GI
NO
VEGF
ERK
REPORTED SEQUENCE
GEPPPGKPADDAGLV
01 / IDENTITY
Quick Facts
A high-level identity and evidence-status dashboard for research review.
GEPPPGKPADDAGLV
Sequence commonly reported in the experimental literature.
Preclinical
Most published findings come from animal or laboratory models.
Investigational
Not an FDA-approved drug and not established for human treatment.
02 / OVERVIEW
What Is BPC-157?
BPC-157 is a synthetic 15-residue peptide frequently described in the scientific literature as a stable gastric pentadecapeptide. Researchers have investigated it across multiple experimental systems, including gastrointestinal injury, connective-tissue models, vascular signaling, and cellular migration.
The key limitation is equally important: broad online claims often extend beyond the available evidence. The published record is dominated by preclinical research, so animal or cell-model findings should not be treated as proof of safety or effectiveness in humans.
03 / PATHWAYS
Proposed Research Mechanisms
Mechanistic themes reported in experimental literature—not confirmed clinical effects.
Nitric-Oxide Signaling
Animal studies frequently examine interactions with nitric-oxide pathways using L-arginine and NOS inhibition models.
PROPOSED PATHWAYVascular Response
Preclinical work has evaluated VEGF expression, endothelial behavior, and context-dependent angiogenic responses.
PRECLINICAL SIGNALCell Migration
Cell and animal models have explored ERK1/2-linked migration, proliferation, and tissue-remodeling signals.
MODEL DEPENDENTMatrix Remodeling
Experimental injury models have measured collagen organization, granulation tissue, and mechanical endpoints.
RESEARCH ENDPOINT
04 / RESEARCH MAP
Areas of Investigation
Organized by experimental question rather than consumer benefit claims.
Gastrointestinal Models
Mucosal injury, ulceration, anastomosis integrity, and inflammatory or oxidative markers.
Tendon & Muscle Models
Fibroblast signaling, collagen organization, vascular response, and mechanical recovery endpoints.
Wound Models
Granulation tissue, re-epithelialization, cellular migration, and extracellular-matrix remodeling.
Vascular Signaling
Nitric-oxide-system interactions, endothelial markers, blood-flow adaptation, and thrombosis models.
Organ-Injury Models
Experimental ischemia, toxic-injury, and oxidative-stress endpoints in animal research.
Evidence Translation
Reproducibility, independent validation, pharmacology, toxicology, and the gap between animal and human evidence.
05 / EVIDENCE
Scientific Evidence Snapshot
A transparent view of what the research record can—and cannot—support.
Evidence tierCurrent signalTranslation confidenceStatus
Animal modelsMultiple experimental systems
Useful for hypothesis generation
SUBSTANTIAL
Cell studiesSelected pathway work
Mechanistic, model dependent
EMERGING
Human evidenceInsufficient controlled data
Cannot establish clinical use
LIMITED
Regulatory reviewSafety information limited
Not FDA-approved
INVESTIGATIONAL
!
Evidence boundary: Preclinical findings do not establish human safety, effectiveness, dosing, or therapeutic use. FDA has noted limited safety-related information and potential concerns involving immunogenicity and peptide-related impurities for compounded BPC-157.
06 / TIMELINE
Research Timeline
Selected milestones showing how the experimental literature expanded.
Early gastric and injury models
Initial animal publications examined mucosal protection, injury response, granulation tissue, angiogenesis, and collagen-related endpoints.
Angiogenesis in muscle and tendon
Published work evaluated VEGF-related markers in cell culture and injured animal tissue, reporting context-dependent vascular modulation.
Cellular pathway studies
Tendon fibroblast and wound-model studies examined growth-hormone-receptor expression, ERK1/2 signaling, migration, and remodeling.
Broader preclinical systems
Animal research continued across gastrointestinal, vascular, ischemia-reperfusion, and multi-organ injury models while human evidence remained limited.
Translation remains the central question
Independent replication, standardized characterization, pharmacokinetics, toxicology, and controlled human data remain major evidence gaps.
07 / SOURCE VAULT
Selected Published Studies
Direct source links are provided for independent review. Inclusion does not imply clinical validation.
2010PRECLINICAL
View the reference framework →
Angiogenesis in muscle and tendon healing
In vitro and animal-model evaluation of VEGF expression and vascular response.
PubMed PMID 20388964 ↗ 2014CELL MODELGrowth-hormone-receptor expression in tendon fibroblasts
Laboratory study examining gene and protein expression in rat tendon fibroblasts.
PubMed PMID 25415472 ↗ 2015PRECLINICALWound model and ERK1/2-linked cellular effects
Murine wound research paired with endothelial-cell migration and signaling assays.
PubMed PMID 25995620 ↗ 2020RAT MODELClopidogrel-induced gastric injury
Animal study assessing mucosal injury, inflammation, apoptosis, and VEGF-related signaling.
PubMed PMID 33376304 ↗
08 / LABORATORY
Study Design & Handling
Methodology-centered guidance for lawful laboratory research—not human-use instructions.
Identity & Documentation
Record batch identity, analytical documentation, material condition, receipt date, and storage history before use.
Controls & Replication
Use appropriate vehicle, positive, and negative controls with predefined endpoints and adequate biological replication.
Cold-Chain Handling
Follow the product label, batch documentation, and laboratory SOPs. Minimize uncontrolled temperature and light exposure.
Transparent Reporting
Document concentrations, preparation methods, model characteristics, exclusions, adverse observations, and complete outcomes.
SRP LABOS
Open Research Calculators ↗
Universal Research Calculator
Open SRP’s calculation workspace for concentration math, unit conversion, scheduling, and research planning.
09 / CLARITY
Frequently Asked Questions
Clear answers that separate published research from unsupported conclusions.
Is BPC-157 approved for human use?+
No. BPC-157 is investigational and is not an FDA-approved drug for human treatment.
What type of evidence exists?+
The published literature is primarily composed of animal studies and selected cell-model experiments. Controlled human evidence is insufficient to establish safety or effectiveness.
What research areas appear most often?+
Frequently studied themes include gastrointestinal injury, connective-tissue models, wound response, vascular signaling, nitric-oxide pathways, and cellular migration.
Does an animal result predict a human outcome?+
No. Animal models are valuable for generating and testing hypotheses, but species differences, experimental conditions, exposure, and study quality limit direct translation.
How is this different from the product page?+
This guide explains the evidence and its limitations. The product page provides batch, purchasing, and research-material information.
10 / REFERENCES
Reference Framework
This starter source vault will expand during the full evidence-writing pass.
- 01
Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing.
PubMed ↗ - 02
Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts.
PubMed ↗ - 03
Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro.
PubMed ↗ - 04
Clopidogrel-induced gastric injury in rats is attenuated by stable gastric pentadecapeptide BPC 157.
PubMed ↗ - 05
FDA: Certain bulk drug substances for use in compounding that may present significant safety risks.
FDA ↗